P53 germline mutations in childhood cancers and cancer risk for carrier individuals
- PMID: 10864200
- PMCID: PMC2363254
- DOI: 10.1054/bjoc.2000.1167
P53 germline mutations in childhood cancers and cancer risk for carrier individuals
Abstract
The family history of cancer in children treated for a solid malignant tumour in the Paediatric Oncology Department at Institute Gustave-Roussy, has been investigated. In order to determine the role of germline p53 mutations in genetic predisposition to childhood cancer, germline p53 mutations were sought in individuals with at least one relative (first- or second-degree relative or first cousin) affected by any cancer before 46 years of age, or affected by multiple cancers. Screening for germline p53 mutation was possible in 268 index cases among individuals fulfilling selection criteria. Seventeen (6.3%) mutations were identified, of which 13 were inherited and four were de novo. Using maximum likelihood methods that incorporate retrospective family data and correct for ascertainment bias, the lifetime risk of cancer for mutation carriers was estimated to be 73% for males and nearly 100% for females with a high risk of breast cancer accounting for the difference. The risk of cancer associated with such mutations is very high and no evidence of low penetrance mutation was found. These mutations are frequently inherited but de novo mutations are not rare.
Similar articles
-
ARCAD: a method for estimating age-dependent disease risk associated with mutation carrier status from family data.Genet Epidemiol. 1995;12(1):13-25. doi: 10.1002/gepi.1370120103. Genet Epidemiol. 1995. PMID: 7713397
-
Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers.Cancer Epidemiol Biomarkers Prev. 2001 Feb;10(2):83-7. Cancer Epidemiol Biomarkers Prev. 2001. PMID: 11219776
-
A method for estimating cancer risk in p53 mutation carriers.Cancer Detect Prev. 1994;18(3):171-8. Cancer Detect Prev. 1994. PMID: 8076379
-
[Germline mutations of the p53 gene].Pathol Biol (Paris). 1997 Dec;45(10):845-51. Pathol Biol (Paris). 1997. PMID: 9769948 Review. French.
-
[Li-Fraumeni syndrome].Bull Cancer. 1997 Jul;84(7):735-40. Bull Cancer. 1997. PMID: 9339200 Review. French.
Cited by
-
The benefit and burden of cancer screening in Li-Fraumeni syndrome: a case report.Yale J Biol Med. 2015 Jun 1;88(2):181-5. eCollection 2015 Jun. Yale J Biol Med. 2015. PMID: 26029016 Free PMC article.
-
Case Report: A Novel Pathomechanism in PEComa by the Loss of Heterozygosity of TP53.Front Oncol. 2022 Mar 28;12:849004. doi: 10.3389/fonc.2022.849004. eCollection 2022. Front Oncol. 2022. PMID: 35419288 Free PMC article.
-
Realizing the promise of cancer predisposition genes.Nature. 2014 Jan 16;505(7483):302-8. doi: 10.1038/nature12981. Nature. 2014. PMID: 24429628 Free PMC article. Review.
-
Breast cancer in young women.Breast Cancer Res. 2010;12(5):212. doi: 10.1186/bcr2647. Epub 2010 Oct 28. Breast Cancer Res. 2010. PMID: 21067532 Free PMC article. Review.
-
Lack of toxicity in a patient with germline TP53 mutation treated with radiotherapy.Curr Oncol. 2014 Apr;21(2):e349-53. doi: 10.3747/co.21.1841. Curr Oncol. 2014. PMID: 24764719 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous